Lucid Diagnostics (LUCD) vs. Its Competitors Head to Head Review

Lucid Diagnostics (NASDAQ:LUCD) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Lucid Diagnostics to related businesses based on the strength of its risk, institutional ownership, dividends, profitability, earnings, analyst recommendations and valuation.

Profitability

This table compares Lucid Diagnostics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lucid Diagnostics	-959.76%	N/A	-119.57%
Lucid Diagnostics Competitors	-9,054.29%	-198.66%	-30.54%

Insider & Institutional Ownership

74.0% of Lucid Diagnostics shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 6.9% of Lucid Diagnostics shares are held by insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Lucid Diagnostics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Lucid Diagnostics	$4.71 million	-$58.01 million	-0.86
Lucid Diagnostics Competitors	$722.78 million	$12.25 million	-10.11

Lucid Diagnostics’ rivals have higher revenue and earnings than Lucid Diagnostics. Lucid Diagnostics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Lucid Diagnostics has a beta of 1.19, indicating that its stock price is 19% more volatile than the S&P 500. Comparatively, Lucid Diagnostics’ rivals have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Lucid Diagnostics and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lucid Diagnostics	1	0	4	0	2.60
Lucid Diagnostics Competitors	9774	15035	45262	1571	2.54

Lucid Diagnostics presently has a consensus target price of $4.19, indicating a potential upside of 934.46%. As a group, “Biotechnology” companies have a potential upside of 95.76%. Given Lucid Diagnostics’ stronger consensus rating and higher probable upside, research analysts plainly believe Lucid Diagnostics is more favorable than its rivals.

Summary

Lucid Diagnostics beats its rivals on 8 of the 13 factors compared.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.